ArticleCell host & microbe2022
Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history.
Registry-linked trialAbstract read
In one paragraph
Article in Cell host & microbe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07287137 (IDCRP-154), which is not on this map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07287137 phase4active not recruitingnot on this mapstarted 2025, after this paper: background citation
IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Who cites it
40 citing papers in PubMed.
- SARS-CoV-2 vaccination and infection elicit cross-neutralizing responses against clade 3 and 4 sarbecoviruses.Nature communications · 2026Article
- Understanding patterns of variant emergence and spread in an ongoing epidemic.medRxiv : the preprint server for health sciences · 2026Article
- Immunogenic relationship mapping supports a minimal-set trivalent vaccine strategy for broad sarbecovirus protection.Signal transduction and targeted therapy · 2026Article
- Combining antigenic data from public sources gives an early indication of the immune escape of emerging virus variants.Scientific reports · 2025Article
- Article
- Comparative Interactome Profiling of Nonstructural Protein 3 Across SARS-CoV-2 Variants Emerged During the COVID-19 Pandemic.Viruses · 2025Article
- Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern.Scientific reports · 2025Article
- Nonhuman primate antigenic cartography of SARS-CoV-2.Cell reports · 2025Article
- Challenges in Humoral Immune Response to Adeno-Associated Viruses Determination.International journal of molecular sciences · 2025Review
- A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection.NPJ vaccines · 2025Article
- Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections.Scientific reports · 2025Article
- Article
- Reduced cross-protective potential of Omicron compared to ancestral SARS-CoV-2 spike vaccines against potentially zoonotic coronaviruses.Npj viruses · 2024Article
- Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.Journal of virology · 2024Article
- High transmission of endemic human coronaviruses before and during the COVID-19 pandemic in adolescents in Cebu, Philippines.BMC infectious diseases · 2024Article
- Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses.PLoS pathogens · 2024Article
- Bioinformatics and molecular biology tools for diagnosis, prevention, treatment and prognosis of COVID-19.Heliyon · 2024Review
- Virus neutralization assays for human respiratory syncytial virus using airway organoids.Cellular and molecular life sciences : CMLS · 2024Article
- Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays.Science translational medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Wei WangCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Sabrina LusvarghiCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Rahul SubramanianOffice of Data Science and Emerging Technologies, Office of Science Management and Operations, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Nusrat J EpsiInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
Richard WangCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Emilie GoguetHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Anthony C FriesU.S. Air Force School of Aerospace Medicine, Wright-Patterson Air Force Base, Fairborn, OH, USA.
Fernando EchegarayViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Russell VassellCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Si'Ana A CogginsHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Stephanie A RichardInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
David A LindholmBrooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, San Antonio, TX, USA; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Katrin MendeInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
Evan C EwersFort Belvoir Community Hospital, Fort Belvoir, VA, USA.
Derek T LarsonFort Belvoir Community Hospital, Fort Belvoir, VA, USA.
Rhonda E ColomboInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Madigan Army Medical Center, Tacoma, WA, USA.
Christopher J ColomboDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Madigan Army Medical Center, Tacoma, WA, USA.
Janet O JosephViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Julia S RozmanInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
Alfred SmithNaval Medical Center Portsmouth, Portsmouth, VA, USA.
Tahaniyat LalaniInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; Naval Medical Center Portsmouth, Portsmouth, VA, USA.
Catherine M BerjohnInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Naval Medical Center San Diego, San Diego, CA, USA.
Ryan C MavesInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Section of Infectious Diseases, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Milissa U JonesTripler Army Medical Center, Honolulu, HI, USA.
Rupal ModyWilliam Beaumont Army Medical Center, El Paso, TX, USA.
Nikhil HuprikarWalter Reed National Military Medical Center, Bethesda, MD, USA.
Jeffrey LivezeyDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
David SaundersDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Monique Hollis-PerryClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD, USA.
Gregory WangGeneral Dynamics Information Technology, Falls Church, VA, USA.
Anuradha GanesanInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; Walter Reed National Military Medical Center, Bethesda, MD, USA.
Mark P SimonsInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Christopher C BroderDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
David R TribbleInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Eric D LaingDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Brian K AganInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
Timothy H BurgessInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Edward MitreDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Simon D PollettInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA. Electronic address: spollett@idcrp.org.
Leah C KatzelnickViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: leah.katzelnick@nih.gov.
Carol D WeissCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. Electronic address: carol.weiss@fda.hhs.gov.
Funding
NIAID NIH HHS Y01 AI005072
Abstract
The rapid emergence of SARS-CoV-2 variants challenges vaccination strategies. Here, we collected 201 serum samples from persons with a single infection or multiple vaccine exposures, or both. We measured their neutralization titers against 15 natural variants and 7 variants with engineered spike mutations and analyzed antigenic diversity. Antigenic maps of primary infection sera showed that Omicron sublineages BA.2, BA.4/BA.5, and BA.2.12.1 are distinct from BA.1 and more similar to Beta/Gamma/Mu variants. Three mRNA COVID-19 vaccinations increased neutralization of BA.1 more than BA.4/BA.5 or BA.2.12.1. BA.1 post-vaccination infection elicited higher neutralization titers to all variants than three vaccinations alone, although with less neutralization to BA.2.12.1 and BA.4/BA.5. Those with BA.1 infection after two or three vaccinations had similar neutralization titer magnitude and antigenic recognition. Accounting for antigenic differences among variants when interpreting neutralization titers can aid the understanding of complex patterns in humoral immunity that informs the selection of future COVID-19 vaccine strains.
Indexed as
COVID-19COVID-19 VaccinesAntibodies, NeutralizingAntibodies, ViralHumansSARS-CoV-2VaccinationAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccinesantigenic cartographyantigenic landscapecartographyCOVID-19 vaccinehybrid immunitymRNA vaccineOmicronSARS-CoV-2SARS-CoV-2 variantsspike
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT07287137ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.